

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

## Managing Hemostasis in Trauma



**NovoSeven® Efficacy and Risk**  
George A. Fritsma, MS MT (ASCP)  
fritsmafactor.com  
george@fritsmafactor.com

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

## 24-YO W♂, GSW in ED

A 24-YO white male arrived in the ED with a gunshot wound causing massive abdominal trauma. He had been given three units of Dextran® in transit to achieve fluid resuscitation but was hemorrhaging. ED personnel ordered and administered four RBC units. Upon the second RBC batch order the transfusion service director recommended one plasma and one pheresis platelet concentrate. After 8 RBCs, 1 plasma, and 1 platelet, still bleeding, labs were:  
PT: 20.8 s (Mean of RI 12.9); PTT: 82.5 s (MRI 30.1)  
FG: 130 mg/dL (200-400 mg/dL); PLT: 70,000/mcl

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

## 24-YO W♂, GSW in ED

In surgery, major vessels were tied, but the field was obscured by microvascular bleeds. The patient went into shock and expired.



Thanks to Mary Anne Krupsky, Michelle Brown, Birmingham, AL and Jose De Jesus, Tuscaloosa, AL for information on which this case is based.

Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006; 105: 198–208.

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

## CDC: WISQARS\*

10 Leading Causes of Death, United States  
2007, All Races, Both Sexes

Rank	ICD-10 Code	Age Group														
		<1	1-4	5-9	10-14	15-24	25-34	35-44	45-54	55-64	65+	All Ages				
1	Ischemic Heart Disease	1,762	1,762	1,762	1,762	1,762	1,762	1,762	1,762	1,762	1,762	1,762	1,762	1,762	1,762	1,762
2	Stroke	1,697	1,697	1,697	1,697	1,697	1,697	1,697	1,697	1,697	1,697	1,697	1,697	1,697	1,697	1,697
3	Accidents (unintentional injuries)	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453
4	Chronic Lower Respiratory Disease	1,385	1,385	1,385	1,385	1,385	1,385	1,385	1,385	1,385	1,385	1,385	1,385	1,385	1,385	1,385
5	Alzheimer's Disease	1,355	1,355	1,355	1,355	1,355	1,355	1,355	1,355	1,355	1,355	1,355	1,355	1,355	1,355	1,355
6	Pneumonia	1,325	1,325	1,325	1,325	1,325	1,325	1,325	1,325	1,325	1,325	1,325	1,325	1,325	1,325	1,325
7	Diabetes Mellitus	1,295	1,295	1,295	1,295	1,295	1,295	1,295	1,295	1,295	1,295	1,295	1,295	1,295	1,295	1,295
8	Chronic Kidney Disease	1,265	1,265	1,265	1,265	1,265	1,265	1,265	1,265	1,265	1,265	1,265	1,265	1,265	1,265	1,265
9	Septicemia	1,235	1,235	1,235	1,235	1,235	1,235	1,235	1,235	1,235	1,235	1,235	1,235	1,235	1,235	1,235
10	Neurodegenerative Diseases	1,205	1,205	1,205	1,205	1,205	1,205	1,205	1,205	1,205	1,205	1,205	1,205	1,205	1,205	1,205

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

## Death by Trauma: Statistics

- Unintended or intentional injury together are the most common cause of death in N Americans age 1–45
  - 93,000/year in the USA (much higher in third world)
- 50% of deaths are caused by severe neurological injury before reaching the hospital
- 20,000 die in hospital of *hemorrhage* within 48 hours
  - 30–35% of blood loss with uncompensated shock is fatal
  - 3–4,000 of hemorrhage deaths are preventable
  - Coagulopathy, failure to achieve hemostasis

Boffard KD, Choop PIT, Kloger Y, et al. The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. On behalf of the NovoSeven Trauma Study Group. Transfusion 2009; 49:240–75.


**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

## Massive Trauma With Hemorrhagic Shock



**Figure 2.** Severely injured patients can present with coagulopathy at the time of hospital admission. This soldier arrived in hemorrhagic shock and required massive transfusion with packed red blood cells (pRBC), coagulation products, and whole blood. Tourniquets were placed on the patient's thighs in the field to minimize blood loss.

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource



Duchesne JC, Holcomb JB. Damage control resuscitation: addressing trauma-induced coagulopathy. *Br J Hosp Med (Lond)* 2009; 70: 22-5.

The Fritsma Factor

7

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Probability of Life-threatening Coagulopathy

Condition (n = 58, >10 RBCs)	% Coagulopathy
Injury severity score (ISS) >25 alone	10%
ISS >25 & systolic BP <70 mm Hg	39%
ISS >25 & body temp <34°C	49%
ISS >25 & pH <7.10	58%
ISS >25; SBP <70 mm Hg; body temp <34°C	85%
ISS >25; SBP <70 mm Hg; temp <34°C; pH <7.10	98%

Life-threatening coagulopathy defined as PT and PTT >2X mean of RI  
[Definition](#) of injury severity score, trauma.org

Cosgriff N, Moore EE, Sauaia A, et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidosis revisited. *J Trauma* 1997;42:857-862

The Fritsma Factor

8

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Coagulopathy in Trauma

ISS & Coagulopathy n = 1088	% Coagulopathy by Lab Assay
Injury severity score (ISS) >15; median 20	57.7%
Injury severity score <15	10.9%
Coagulopathy at Admission	% Mortality
Yes (24.4%)	46%
No	10.9%
Overall mortality	19.5%

Coagulopathy defined prior to & independent of fluid replacement as: PT >18s, 16.3%; PTT >60s, 24.4%; or TT >15s, 14.2%

Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. *J Trauma* 2003; 54: 1127-30

The Fritsma Factor


9

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### PT and PTT Predict Mortality

- Review of 7638 level I trauma admissions
- Initial PT >14s: 28%
  - 6.3% of patients with PT <14s died
  - 19.3% of patients with PT >14s died
  - Independent mortality increase 35%; OR, 3.6; p <0.0001
    - When controlling for age, ISS, BP, HCT, pH, and head injury
- Initial PTT >34s: 8%
  - Independent mortality increase 326%; OR 7.8; p <0.0001

MacLeod JB, Lynn M, McKenney MG, et al. Early coagulopathy predicts mortality in trauma. *J Trauma* 2003;55:39-44.



The Fritsma Factor

10

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Massive Tx Requirement Likely In Young, Healthy Casualties When...

- Systolic <110 mm Hg
- Pulse >105
- pH <7.25
- HCT <32%
- HGB <10 g/dL
- INR >1.5 (Is INR the correct measure?)

McLaughlin DF, Niles SE, Salinas J, et al. A predictive model for massive transfusion in combat casualty patients. *J Trauma* 2008;64:S57-63.  
Schreiber MA, Perkins J, Kiraly L, et al. Early predictors of massive transfusion in combat casualties. *J Am Coll Surg* 2007;205:541-5

The Fritsma Factor

11

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### American Society of Anesthesiologists Surgical Practice Guidelines: RBCs

- Monitor BP, pulse, ABG (pH, O<sub>2</sub> sat), urine output, EKG when feasible
- Monitor physical blood loss
- Transfuse when HGB <6 g/dL in young, healthy patient
- Do not transfuse when HGB >10 g/dL
- Based on acuity and clinical history when HGB 6–10 g/dL
  - O<sub>2</sub> sat, tissue ischemia, bleeding rate, IV volume replacement, evidence for coagulopathy
- Autotransfuse (recovery) when feasible




The Fritsma Factor

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### American Society of Anesthesiologists Practice Guidelines: *Coagulopathy*

- Assess surgical field for microvascular bleeding
  - Suction canisters, surgical sponges, surgical drains
- Platelet concentrate transfusion
  - No platelets if count is >100,000/mcL
  - “Usually” give platelets if <50,000/mcL, unless...
    - Limited blood loss is anticipated based on type of surgery
    - If thrombocytopenia is due to HIT, ITP, or TTP, where platelets are ineffective
  - From 50–100,000/mcL, use platelets if...
    - Potential of bleeding into confined space such as brain or eye
    - Aspirin, clopidogrel, cardiopulmonary bypass, platelet disorder

Duchesne JC, Holcomb JB. Damage control resuscitation: addressing trauma-related coagulopathy. *Br J Hosp Med (Lond)* 2009; 70: 22–5.




The Fritsma Factor

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### American Society of Anesthesiologists Practice Guidelines: *Coagulopathy*

- Give plasma if microvascular bleeding...
  - And PT >1.5X normal (“normal” is undefined),
  - Or PTT >2X normal,
  - Or when transfused with >1 blood volume (~70 mL/kg),
  - Or need for urgent reversal of warfarin therapy,
  - Or known factor deficiency & concentrate is unavailable,
  - Or heparin resistance (antithrombin deficiency).
- Do not use plasma only to augment volume, use colloid plasma expanders
- Dosage is 10–15 mL plasma/kg to achieve ≥30% factor concentration
  - Or 5–8 mL/kg if only for warfarin reversal




The Fritsma Factor

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### American Society of Anesthesiologists Practice Guidelines: *Coagulopathy*

- CRYO when there is microvascular bleeding and...
  - Fibrinogen <100 mg/dL or documented deficiency,
  - Or massive transfusions without opportunity to determine fibrinogen level
- CRYO delivers 150–250 mg fibrinogen
- Consider rFVIIa when RBCs, PLTs, plasma and CRYO fail to stop microvascular bleeds



The Fritsma Factor

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### RBC/Plasma 1:1?

- USA hospital in Baghdad Green Zone
  - Retrospective w/o controls but extensive, accurate data
  - Tx >2000 wounded, massively Tx >600 wounded
- Ratio and results
  - Receiving <1 plasma/4 RBCs: 65% mortality
    - Confounding data: soldiers who received >10 RBCs but died before plasma could thaw are counted in this arm
  - Receiving 2 plasma/3 RBCs: 19% mortality
    - Surgeons report less bleeding and edema
  - Now implementing 1:1 plasma/RBC Rx
- Anticipated adverse effects; none recorded
  - Plasma supply, TRALI, anaphylaxis, ARDS, MOF, thrombosis


Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affect mortality in patients receiving massive transfusions in a combat support hospital. *J Trauma* 2007; 63: 805–13.

The Fritsma Factor

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### Recombinant Activated Factor VII

- Pre-1980 (and still available)
  - Prothrombin complex concentrates (PCC) extracted from human plasma using Ba<sub>2</sub>SO<sub>4</sub> absorption: Proplex®
    - Factors II, VII, IX, and X, once used for IX deficiency patients
  - Activated PCC for FVIII or FIX deficiency with inhibitors
    - FEIBA FH®
    - Variant efficacy traced to FVIIa activity
- 1980: Extract FVIIa from human plasma
  - Kiesel, Broze
- 1983: Compassionate use in two humans
- 1988: Novo Nordisk®, Bagsvaerd, Denmark, undertook to synthesize rFVIIa
- March 25, 1999: FDA releases NovoSeven® rFVIIa



Kiesel W. Recollections on the discovery of factor VIIa as a novel therapeutic agent for hemophiliacs with inhibitors. *J Thromb Haemost* 2009; 7:1053–6.



Broze GJ, Majerus PW. Purification and properties of human coagulation factor VII. *J Biol Chem* 1980; 255:1242–7.

The Fritsma Factor

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### rFVIIa; NovoSeven

- Secreted from baby hamster kidney cells, proteolytically converted to two-chain active form
- Limitation: γ-carboxylation of 2/3 of glutamic acids at carboxy terminus
  - Seems to be enough γ-carboxylated GLUs
  - Requires coexpressed γ-glutamyl carboxylase
  - Requires vitamin K

The Fritsma Factor

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource


### Physiology of rFVIIa & Tissue Factor

- rFVIIa binds TF of injured vessels, activating FX; FXa binds FV; activates II→IIa; generates fibrin
- rFVIIa activates platelets directly through thrombin receptors and triggers primary coagulation even in Glanzmann thrombasthenia
- rFVIIa activates *thrombin activatable fibrinolysis inhibitor* (TAFI), simultaneously reduces fibrinolysis
- rFVIIa hemostatic action is localized by TF
  - FEIBA functions systemically
  - DIC risk is negligible

Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders—a 2006 review. *Haemophilia* 2006;12:457–72.  
Hedner U, Kiesel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. *J Clin Invest* 1983;71:1836–41.

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource


### Coagulation Pathway



Fritsma MG, Fritsma GA. Overview of Hemostasis and Coagulation. In Rodak BF, Fritsma GA, Keohane E. *Hematology*, 4th Edition, Elsevier 2011


**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

### Platelet Receptors (and 50 more)



**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

### Fibrinolysis



**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

### rFVIIa 3/25/99 FDA Indications

- Bleeding episode Rx in hemophilia A or B with inhibitors or in acquired hemophilia
- Bleeding prevention in invasive procedures in hemophilia A or B with inhibitors or acquired hemophilia
- Bleeding Rx in congenital FVII deficiency
- Bleeding prevention in invasive procedures in congenital FVII deficiency



**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

### Applications for Off-label rFVIIa

- Cardiac, thoracic, aortic and spinal surgery; hepatic resection; hysterectomy or post-partum bleeding
- Severe multiple trauma
- Non-traumatic intracranial hemorrhage if <4 hours from onset
- Reversal of antithrombotic (warfarin) overdose

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource



### rFVIIa Dosages Cleared by FDA

Cleared Indication	IV Bolus Dose
Hemophilia A or B with inhibitor—bleeding episodes	90 mcg/kg every 2 h until hemostasis is achieved
Hemophilia A or B with inhibitor—surgery	90 mcg/kg immediately before and every 2 h during surgery
• Post-surgery minor	90 mcg/kg every 2 h for 48 h, then every 2–6 h until healed
• Post-surgery major	90 mcg/kg every 2 h for 5 d then every 2 h until healed
Congenital FVII deficiency—bleeding episode or surgery	15–30 mcg/kg every 4–6 h until healed
Acquired hemophilia—bleeding episode or surgery	70–90 mcg/kg every 2–3 h until hemostasis is achieved
Cost \$1.00/mcg, single Rx for a 70 kg patient is \$6300	

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource



### Generalized Off-label Guidelines for rFVIIa

- Evaluate underlying disorder
- Evaluate salvageability of the patient
- Ensure no inherent thrombophilia, prior AMI or stroke
- Exhaust current treatment options
  - RBCs, plasma, PLTs, CRYO
- Document amount of blood products used
- Ensure pH >7.25

Mathew P, Simon TL, Hunt KE, Crookston KP. How we manage requests for recombinant factor VIIa (NovoSeven). *Transfusion* 2007;47:8–14.

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource



### Generalized Off-label Guidelines for rFVIIa

- Always offer rFVIIa when bleeding continues after conventional Tx therapy
  - RBC, plasma, platelets, and CRYO
  - rFVIIa doesn't work when coagulation factors <30%
- Contraindicated in previous thrombosis
  - Stroke: ensure it is intracranial hemorrhage
  - Assume no thrombosis in young trauma victims
- 20–40 mcg/kg in non-emergent warfarin reversal
- 40–90 mcg/kg in adults for all emergent scenarios

Personal communication, R. Sarode, MD, Director, Transfusion Medicine and Hemostasis Reference Laboratory, UT Southwestern MC, Dallas, TX

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource



### Acute Care Facility rFVIIa Guide

- Post-cardiac surgery
  - 90–120 mcg/kg, 1–2 doses at 2h intervals, rarely 3
  - Treat to bleeding cessation
- Newborns
  - Split vial into 4–6 aliquots, use all within 24 hours
  - 90–120 mcg/kg at 2h intervals, treat to normalized PT
  - *Not recommended* by Novo Nordisk
- Glanzmann, congenital platelet disorders
  - Often children, dose accordingly
  - Avoids alloimmunization to platelet concentrates
  - 90–120 mcg/kg, 2h intervals, treat to bleeding cessation
- Trauma
  - 90–120 mcg/kg, second at 2h 40–60, rarely 3
- Intracranial hemorrhage
  - 90–120 mcg/kg, 2h intervals, treat to control expansion
  - Observe resolution of neurological symptoms
  - 3.5x odds for serious thromboembolic event

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource



### Off Label Use in Trauma: 2005

- Israeli soldier with bleeding rescued by rFVIIa
- Approved by USA surgeon general for battlefield
- Case reports of efficacy and research protocols by Col. John B. Holcomb, MD
  - Commander of the US Army Institute of Surgical Research, Ft Sam Houston, TX, and Trauma Consultant for The Army Surgeon General



The Fritsma Factor

Allen JA, Benner K, Green K, et al. Pediatric off-label use of recombinant factor VIIa. *Pediatrics* 2009;123:1066–72.  
 Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. *Crit Care Med* 2005;33:883–90.  
 Tatoulis J, Theodore S, Meswani M, et al. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery. *Interact Cardiovasc Thorac Surg* 2009;9:459–62.  
 Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. *J Thromb Haemost* 2005;3:640–8.

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource



### Spinella: Iraq Combat Trauma

- Retrospective case-control study of 124 severe Iraq combat trauma patients
  - ≥ 10 units RBCs/24h
- Determine if rFVIIa reduces 24 h and 30 d mortality
- Determine association of rFVIIa with severe VTE

One 120 mcg/kg dose	Means	
	75 Controls	49 rFVIIa
RBC (units)	14	16
Plasma (units)	8	10
Fresh whole blood (units)	0	4
Cryo (units)	0	10

Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. *J Trauma* 2008; 4: 286–93.

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Spinella: Mortality Rate in Iraq

All-cause Mortality	75 Controls	49 rFVIIa	P
12 h	25 (33%)	6 (12%)	.008
24 h (cumulative)	26 (35%)	7 (14%)	.01
30 d (cumulative)	38 (51%)	15 (31%)	.03
Thromboembolism	0	2	.15
37 patients died from hemorrhage	29 (78%)	8 (57%)	.12

The Fritsma Factor

31

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Cameron: Blood Products Australia and New Zealand

- Uncontrolled retrospective registry data of 108 patients receiving rFVIIa for trauma
- Two PEs, 1 CVA, 1 DIC

Median Dose 90 mcg/kg	Median Pre-rFVIIa	Median Post-rFVIIa	P
RBCs	16	3	< .001
Plasma	8	1	< .001
PLT	3	0	< .001
CRYO	5	0	< .001
PT/INR	Shortened/reduced		< .001
PTT	Shortened		.004

Cameron P, Phillips L, Balogh Z, et al. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry. *Injury* 2007; 38: 1030-8.

The Fritsma Factor

32

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Harrison: General Trauma

- Prospective study of rFVIIa-treated trauma patients matched to historic controls
- Mortality rates 41% in rFVIIa, 40% in controls (NS)
- Thromboemboli in 6.9% of rFVIIa, 19.7% of controls; (P=0.2)

1-240 mcg/kg doses	Means (SD not shown)	P	
Transfusion	72 Controls	29 Cases	
RBC (units)	22.0	18.3	.036
Plasma (units)	14.1	14.2	NS
PLT (5-pack units)	2.3	1.4	.01
Cryo (5-pack units)	1.5	0.59	.006

Harrison TD, Laskosky J, Jazayeri O, et al. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. *J Trauma* 2005; 59: 150-4.

The Fritsma Factor

33

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Tx Requirements: 48 Hours After First Dose of rFVIIa

	Placebo		rFVIIa		P
	N	Median	N	Median	
RBC (units)	65	6.6	48	2.9	<0.001
Plasma (mL)	54	1400	35	660	0.001
PLT (mL)	62	300	46	50	0.01

- Incidence of MOF or ARDS was 20% for placebo, 3% for rFVIIa, P=.004
- Incidence of thromboembolic events was 4% for placebo and 3% for rFVIIa, P=1.00

Duchesne JC, Holcomb JB. Damage control resuscitation: addressing trauma-induced coagulopathy. *Br J Hosp Med* 2009;70: 22-5.

The Fritsma Factor

34

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### FDA Reports Thromboembolic Events

Divs. of Epidemiology and Hematology collected adverse event data 3/25/99-12/31/04, all US and non-US patients including post-licensure clinical trials




Figure 1. Estimated Number of Patients Treated With Recombinant Human Coagulation Factor VIIa by Year

O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA* 2006;295:293-8.

The Fritsma Factor

35

Table 1. Number of Thromboembolic Event Reports With Use of rFVIIa by Report Source and Reason for Use and Bleeding Status

Reason for use	No. of Reports (%)	
	Trial (n = 59)	Spontaneous (n = 109)
Surgery (bleeding or prophylaxis)	27 (46)	48 (44)
Intentional bleeding	19 (32)	5 (5)
Bleeding, nonsurgical	8 (14)	25 (24)
Trauma, nonsurgical	5 (9)	9 (8)
Hemophilia	0	17 (16)
Unknown*	0	4 (4)
Bleeding status		
Active bleeding	35 (59)	80 (73)
Prophylaxis	24 (41)	22 (20)
Unknown*	0	7 (7)


Abbreviation: rFVIIa, recombinant human coagulation factor VIIa.  
\*Indicates no information about reason for use or whether patient was bleeding or not.

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Thrombotic Events and Deaths

168 reports: 183 thrombotic events, 52 deaths


Figure 3. Number of Thromboembolic Event Reports With Recombinant Human Coagulation Factor VIIa Reported to FDA by Source and Year



FDA indicates US Food and Drug Administration. Some reports had more than 1 thromboembolic event.

The Fritsma Factor

Figure 4. Number of Reported Deaths Among Patients Administered Recombinant Human Coagulation Factor VIIa With a Thromboembolic Event by Year and Source



FDA indicates US Food and Drug Administration.

The Fritsma Factor

36

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### Thrombotic Event Sites

Site	Number (%)
Ischemic stroke	39 (21.3%)
Acute myocardial infarction	34 (18.6%)
Peripheral artery occlusion	26 (14.2%)
Deep venous thrombosis	42 (22.9%)
Pulmonary embolus	32 (17.5%)
Occluded line	10 (5.5%)
<b>Total</b>	<b>183 (100%)</b>
Patients in 5-y survey	~10,700
Rate of thrombotic events	0.017%

The Fritsma Factor

37

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### London Times, September 17, 2006

#### "Wounded Iraq Troops Given Danger Drug"

"The Ministry of Defense has been accused of playing 'Russian roulette' with soldiers' lives after it admitted using an unlicensed drug linked to 67 deaths in America. Troops suffering severe injuries in Iraq have been treated with NovoSeven®, a drug licensed only for hemophiliacs."

**Warning: Serious thrombotic adverse events are associated with the use of NovoSeven® RT outside labeled indications**

Arterial and venous thrombotic and thromboembolic events following administration of NovoSeven® have been reported during postmarketing surveillance. Clinical studies have shown an increased risk of arterial thromboembolic adverse events with NovoSeven® RT when administered outside the current approved indications. Fatal and non-fatal thrombotic events have been reported. Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT. Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis. See **WARNINGS AND PRECAUTIONS** section of prescribing information. **Safety and efficacy of NovoSeven® RT has not been established outside the approved indications.**

The Fritsma Factor

38

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### Subsequent Discussion

**Recombinant Factor VIIa and Thrombotic Events**

To the Editor, Dr O'Connell and colleagues<sup>1</sup> reviewed thrombotic complications of recombinant human coagulation factor VIIa (rFVIIa) as reported to the US Food and Drug Administration (FDA) MedWatch database. As with any medication, rFVIIa has both positive and negative effects. Therefore, risks and benefits must be considered before administering the drug. In our trauma practice, we cannot know which of our patients with life-threatening hemorrhage are also at risk for ischemic stroke, myocardial infarction, or other thrombotic complications. We are cautious with rFVIIa use in the presence of arterial injury and will not use it in patients undergoing extracorporeal circulatory support. However, some patients have dilutional coagulopathy severe enough to warrant the use of almost any therapy to salvage them from hemorrhagic shock, regardless of risk.<sup>2</sup> A recent randomized, placebo-controlled, double-blind trial of the use of rFVIIa in patients who did not find an increased risk of thrombotic events.<sup>3</sup> This study, however, excluded patients older than 65 years, who would be most likely to experience adverse thrombotic events.

Less clear to us is the risk-benefit ratio for off-label rFVIIa use in patients who are not in extremis. One frequent use of rFVIIa is the reversal of warfarin therapy in patients presenting with active bleeding, such as those patients with subdural hematoma. Coagulation may be normalized more rapidly than with traditional administration of plasma, with a decreased risk of fluid overload. It would therefore be helpful to know how many of the reported thrombotic complications described by O'Connell et al were observed in patients who were taking warfarin analogs or platelet inhibitors before the rFVIIa

dose, what proportion of the prophylactic use was in patients with conditions such as cirrhosis that are associated with coagulopathies, and what proportion was in patients with normal coagulation systems.

Finally, the comments on the study of rFVIIa in patients with intracranial hemorrhage<sup>4</sup> were valuable, because this was the first prospective study to suggest a dose-response effect in the thrombotic complication rate. Understanding the risks of rFVIIa will be enhanced if reports to MedWatch include the dose of drug administered, other pro-coagulant therapies, underlying pathophysiology, and the timing of complications. Such detail may help in designing future trials of rFVIIa.

Richard P. Dutton, MD, MBA  
rdutton@mayo.edu  
Dobrosz M. Stein, MD, MPH  
John R. Hines, MD, MPH  
Thomas M. Scalea, MD  
The R. Adams Cowley Shock Trauma Center  
University of Maryland Medical System  
Baltimore

**Financial Disclosure:** Dr Dutton reported owning as a research design consultant for Novo Nordisk, the manufacturer of rFVIIa. Dr Stein reported that he or she has financial interest in Novo Nordisk. No other authors reported financial disclosures.

- O'Connell KA, Wood JJ, Wise SP, Laster JH, Braun MM. Thrombotic adverse events after use of recombinant human coagulation factor VIIa. *JAMA*. 2006;295:2973-2978.
- Scalea TM, et al. Recombinant factor VIIa for correction of traumatic coagulopathy. *J Trauma*. 2004;57:2028-19.
- Refracta F. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind trials. *J Trauma*. 2009;66:18-19.
- Mayer SA, Stein MC, Brogton M, et al. Recombinant activated factor VII for acute intracranial hemorrhage. *N Engl J Med*. 2008;359:977-985.

The Fritsma Factor

39

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### Response by Authors

**In Reply:** The comments from Dr Dutton and colleagues emphasize the importance of benefit-risk considerations for patients in extremis vs those who are not. Available information from the FDA's database of 188 patients with post-rFVIIa thrombotic events does not include sufficient detail to respond to all of their questions. However, regarding prophylactic use, the records identify only 1 patient who underwent warfarin reversal. An elderly man with an international normalized ratio of 2.7 received fresh-frozen plasma (6 units) and 2.4 mg of rFVIIa (30 µg/kg) before evacuation of a subdural hematoma, and vitamin K after surgery. Pulmonary embolism was diagnosed 3 days later. Among 49 reports of prophylactic rFVIIa use, 26 specifically mentioned the presence of serious liver disease.

We agree about the importance of reporting serious adverse events to the FDA's MedWatch program and including as complete detail as possible. These anecdotal reports can contribute to the design of needed prospective trials. Clinicians can easily provide reports of adverse events via the online MedWatch reporting system,<sup>1</sup> download the voluntary reporting form and fax it to 1-800-FDA-1088, or call

1-800-FDA-1088 to report by telephone. Alternatively, adverse events can be reported to the product manufacturer, who is then required to report to the FDA.

Kathya A. O'Connell, MD, PhD  
kathya.oconnell@fda.gov  
Robert P. Wise, MD, MPH  
Division of Epidemiology  
John S. Laster, MD, PhD  
Division of Hematology  
Office of Blood Research and Review  
M. Miles Braun, MD, MPH  
Division of Epidemiology  
Center for Biologics Evaluation and Research  
Food and Drug Administration  
Rockville, Md

**Financial Disclosures:** None reported.

1. Voluntary reporting by health professionals. US Food and Drug Administration. <http://www.fda.gov/oc/medwatch/medwatch.htm>. Accessed March 14, 2008.

44. *JAMA*. July 5, 2006;296:No. 1 (Reprinted)

The Fritsma Factor

40

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### Novo Nordisk Phase 2 Trial

- Multicenter prospective randomized double-blind placebo-controlled trial evaluated effect of rFVIIa on RBC transfusion requirements in patients with blunt or penetrating trauma
- 277 patients, 143 blunt, 134 penetrating
  - Criteria: required 6 RBC units within 4 hours of admission
- Placebo or rFVIIa at 0 h (200 mcg/kg), 1 h (100 mcg/kg), and 3 h (100 mcg/kg)
- Adverse events: adult respiratory distress syndrome (ARDS), multi-organ failure (MOF) and thromboembolic events (TE)

Bruder E, Howes DW. rFVIIa in trauma: A review and opinion-based guidelines. *Trauma* 2007; 9: 237-43.

The Fritsma Factor

41

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

### rFVIIa Phase III Trial Withdrawal

**Background:** Hemorrhage contributes significantly to multiple organ failure (MOF) and death following severe injury. We performed a multicenter, international, placebo controlled Phase III trial to evaluate recombinant activated factor VII (rFVIIa) as an adjunct to standard hemostatic methods in trauma patients presenting in hemorrhagic shock. We assessed the safety of rFVIIa and its efficacy in improving survival, reducing blood loss, and decreasing MOF.

**Methods:** 573 actively bleeding patients (481 blunt, 92 penetrating), who had received 4-8 units of blood within 12 h of injury and had evidence of ongoing hemorrhagic shock were randomly assigned to receive rFVIIa (200 µg/kg at 0 h, 100 µg/kg at 1 h and 3 h) or placebo. Clinical care was standardized according to evidence-based guidelines. The primary outcome was 30-day mortality. Secondary outcomes included total allogeneic blood product transfusions and the incidence and duration of organ failure. Safety and clinical outcomes were assessed to 90 days.

**Results:** The study was terminated prematurely after 573 patients (1502 initially planned) because an unexpectedly low mortality rate (~10%) precluded demonstration of efficacy. No difference in 30-day mortality was observed ( $P = 0.93$ ). rFVIIa decreased total blood product use at 48 h compared with placebo in blunt trauma patients (23.5 vs. 19.0 units;  $P = 0.04$ ). There were no differences in the incidence or duration of organ failure ( $P = 0.09$ ). There were no differences in adverse events, including thromboembolic events.

**Conclusions:** Treatment of blunt trauma patients in hemorrhagic shock with rFVIIa decreased blood product use without an observed increase in thromboembolic complications, but did not demonstrate improvement in organ system failure or mortality.

Hauser CJ, Boffard KD, Dutton RP, et al. Efficacy and safety of recombinant activated factor VII in the management of hemorrhagic shock due to trauma. *J Thromb Haemost* 2007; 7(Suppt2):290-1.

The Fritsma Factor

42

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

## Baltimore Sun, May 16, 2010

### Federal agents probing Army's use of trauma drug

Criminal investigation looking at military's use of blood-clotting injections for treating war casualties

May 16, 2010 | By Robert Little, The Baltimore Sun



Sun photo by Monica Lopez

Federal criminal investigators are exploring the Army's use of a controversial and expensive blood-clotting drug injected into wounded troops in Iraq and Afghanistan. The drug, called Factor VII, was hailed as a lifesaving breakthrough by military leaders and administered to hundreds of soldiers and Marines earlier in the wars. It has since proved largely ineffective in clinical trials and been the subject of safety warnings by U.S. and European regulators, who say it can cause potentially deadly blood clots.

Within the past several weeks, agents from the Army's Criminal Investigation Command have interviewed scientists and officers at the Army's medical laboratory in San Antonio about Factor VII, according to military sources with knowledge of the investigation. Researchers in San Antonio were among the first to explore Factor VII's role in treating trauma patients and have produced some of the few scientific studies suggesting that the drug saves lives in combat.

The manufacturer, the Danish drug company Novo Nordisk, said it had received a subpoena in January from the Defense Department's inspector general's office. Company officials said they are cooperating with the U.S. attorney's office in Baltimore, which is overseeing the investigation.

The Fritsma Factor

43


**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

## Laboratory Monitoring

- PT, PTT, FG, D-dimer, PLT count
  - Broad assessment, not accurate for dosing
- Global hemostasis: thromboelastograph



The Fritsma Factor



44

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

## Thromboelastogram




Figure 4. Thromboelastograph (TEG) tracing. The reaction time (R) represents the time to onset of clot formation. K time is a measure of the speed to reach a certain level of clot strength.  $\alpha$  angle represents the rate of clot formation. The maximum amplitude (MA) measures the clot strength. Reprinted with permission from Kiraly, J Trauma 2006;61:57-64.

The Fritsma Factor

45

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

## Coagulopathy and Shock

- 208 pts, 75% male, level I trauma center
  - 3/03 to 6/04
- Specimens within 10 minutes of arrival
  - PT, PTT
  - Base deficit (BD, metabolic acidosis): measure of shock
- Assays made at conclusion of study
  - Plasminogen activator inhibitor 1 (PAI-1)
  - Prothrombin fragment 1+2 (PF 1+2)
  - Soluble thrombomodulin (TM)
  - Protein C activity (PC)
  - Fibrinogen (FG)
  - D-dimer (DD)


Brohi K, Cohen MJ, Ganter MT, et al. Acute traumatic coagulopathy: initiated by hypoperfusion, modulated through the protein C pathway? Ann Surg 2007; 245: 812-8.

The Fritsma Factor

46

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

## Fibrinolysis: Plasminogen Activation




TPA: Tissue plasminogen activator  
PAI-1: Plasminogen activator inhibitor-1  
TAFI: Thrombin activatable fibrinolysis inhibitor

The Fritsma Factor

47

**THE FRITSMFA FACTOR**  
Your Interactive Hemostasis Resource

## PT, PTT Versus Base Deficit



A and B: PT and PTT as a function of BD  
C and D: PT and PTT prolonged in BD, PF1+2 baseline


The Fritsma Factor

48



**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### TM and PC Versus BD and PF 1+2




A and B: TM rises and PC drops as a function of BD  
C: PC drops as a function of [PF 1+2] only in BD  
D: PC drops as a function of [PF 1+2] only in TM rise

The Fritsma Factor 49

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### PT, PTT, PAI-1, D-D Versus PC




A and B: PTT and PT prolong as PC drops  
C: PAI-1 drops as PC drops  
D: D-dimer rises as PC drops

The Fritsma Factor 50

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### PC, TM Versus Mortality



A: Mortality as PC drops  
B: Mortality as TM rises

The Fritsma Factor 51

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Conclusions Early Post-injury Coagulopathy

- Coagulopathy not due to reduced coagulation factors
- Fibrinogen levels normal in all patients
- PT and PTT prolonged only in increased BD (shock)
- TM rises and PC falls in increased BD
- Activated PC depletes PAI-1
  - Reduced inhibition of tissue plasminogen activator
  - Increased fibrinolysis

Brohi K, Cohen MJ, Ganter MT, et al. Acute Traumatic Coagulopathy: Initiated by hypoperfusion, modulated through the protein C pathway? Ann Surg 2007; 245: 812-8.

The Fritsma Factor 52

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Coagulopathy Mechanism

- No contribution to incidence or degree of admission coagulopathy
  - Coagulation factor consumption
  - Dilution, hypothermia, acidosis
- Shock and coagulopathy
  - Increased soluble TM
  - PC activation
  - PAI-1 consumption, increased fibrinolysis
- Treatment implications


Brohi K, Cohen MJ, Ganter MT, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 2008; 46: 1211-7.

The Fritsma Factor 53

**THE FRITSMFACTOR**  
Your Interactive Hemostasis Resource

### Tranexamic Acid (Cyclokapron) Rx

- Synthetic lysine blocks plasminogen binding sites
  - Cyclohexane carboxylic acid
- Reduces Tx requirements in surgery without change in mortality




CRASH-2 trial collaborators (570). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. The Lancet 2010; 376: 23-32



The Fritsma Factor 54

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

### CRASH-2



The Fris

55

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

### Tranexamic Acid Death by Cause

	Tranexamic acid	Placebo	RR	p
	n = 10060	n = 10067		
<b>Any cause of death</b>	1463 (14.5%)	1613 (16%)	0.91	0.0035
<b>Bleeding death</b>	489 (4.9%)	574 (5.7%)	0.85	0.0077
<b>Vascular occlusion death</b>	33 (0.3%)	48 (0.5%)	0.69	0.096
<b>No dependency symptoms</b>	1334 (13.3%)	1334 (13.3%)	1.11	0.0023


No significant differences: MI, stroke, PE, DVT, blood products, surgery

The Fris

56

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

### All-cause Mortality by Subgroups




The Fris

57

**THE FRITSMa FACTOR**  
Your Interactive Hemostasis Resource

### Summary: ACOTS



Modified from: Tieu BH, Holcomb JB, Schreiber MA. Coagulopathy: its pathophysiology and treatment in the injured patient. World J Surg 2007 31: 1055-64

The Fris

58